Navigation Links
Two Novel Lilly Molecules Target Genetic Mutations That Can Lead to Cancer
Date:4/4/2011

ORLANDO, Fla., April 4, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results today from two preclinical studies of molecules that target genetic mutations and disable specific signaling pathways that can lead to cancer.  The studies evaluated two unique molecules – a JAK2 inhibitor and a Hedgehog inhibitor – with results presented during the American Association for Cancer Research (AACR) 102nd Annual Meeting in Orlando, Fla.  

Signaling pathways within cells regulate genes that underlie crucial biological processes including cell division, embryonic development and immunity.  When these networks of proteins misfire, many types of cancer can result.  At AACR, data from Lilly showed how these pipeline molecules target out-of-control signaling pathways.

"Lilly is focused on developing therapies tailored for an individual patient's needs – such as a cancer treatment that targets a specific genetic mutation," said Jonathan M. Yingling, Ph.D., vice president of oncology research at Lilly.  "We believe beginning this evaluation early in the preclinical stage, as we have with these two studies, may lead to more focused, efficient clinical trials and, in turn, speed drug discovery."

LY2784544: JAK2 Inhibitor (Abstract # 2820)

Research presented at AACR's New Small Molecule Therapeutics mini-symposium suggested that the investigational compound LY2784544, a small-molecule JAK2 inhibitor, blocks a specific, difficult-to-isolate, signaling pathway that can lead to the development of cancer cells.  

Specifically, Lilly researchers chose to study inflammatory breast cancer (IBC) cells because these cells support their own survival by secreting chemicals known as growth factors, which allow them to break away from the primary tumor, multiply and then cluster together into tumor sp
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Research and Markets ( http://www.researchandmarkets.com/research/vzhr6h/video ) has announced ... Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" ... been the topic of fascination since the era of the ... and the Soviet Russia. Earlier even a small glimpse of ...
(Date:1/23/2015)... Jan. 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... therapies for operable and inoperable solid tumor cancers, announced today ... 7 th Annual Phacilitate Immunotherapy Forum in ... Phacilitate will take place on January 26 at 10:30 a.m. ...
(Date:1/23/2015)... all-time hits leader, is the new spokesperson for the topical ... announced. "Pete,s a Hall of Famer in our ... with Myoflex," said Ducere Pharma Chief Executive Officer Chris ... across all generations. The passion and intensity that Pete brought ...
Breaking Medicine Technology:Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Video Telemedicine Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Pete Rose bets on Myoflex to relieve aches and pains 2
... , SOUTH PLAINFIELD, N.J. , ... announced the initiation of an additional clinical trial of ataluren ... Becker muscular dystrophy (nmDBMD) who have permanently lost the ... methods for measuring functional abilities in patients who have lost ...
... , NEW YORK , Jan. 19 ... Increase Exposure to Non-Cyclical, Laggard Sectors; Maintain Exposure to US ... phase of recovery is over, markets are moving into a ... investors are paying more attention to valuations, particularly in the ...
Cached Medicine Technology:PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 2PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 3PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 4PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 5PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy 6Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms 2Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms 3Barclays Wealth Recommends Increasing Exposure to Laggard Sectors Including Consumer Staples, Pharmaceuticals and Telecoms 4
(Date:1/22/2015)... 2015 The City of West Hollywood hosted a ... commemorate the 42nd anniversary of the Supreme Court decision Roe v. ... 42 years since the Roe vs. Wade decision and the fight ... as ever,” said City of West Hollywood Councilmember Abbe Land. “We ...
(Date:1/22/2015)... Gabe’s Chemo Duck Program is pleased to announce the release of ... kids with cancer. The Chemo Duck App, available on iTunes for ... games to help children of all ages living with cancer adjust ... kids entertained, educated and at ease while waiting for clinic visits ...
(Date:1/22/2015)... January 23, 2015 VogueQueen is a seasoned ... prices and many designers are thrilled to have it lead ... announces its new collection of prom dresses for the global ... drive the strategic vision and he focuses on continuing the ...
(Date:1/22/2015)... is a famous wedding dress company offering many trendy designs. ... Facebook, Twitter, and Pinterest. The fans will have an opportunity ... every week. , Moreover, the company has extended its 2015 ... homepage for more information. , Angelweddingdress is a ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has recently released ... website of AngelWeddingDress.com to find more details. , ... for a bridal party. AngelWeddingDress offers a variety of ... maternity wedding dresses are specially designed for 2015. , ...
Breaking Medicine News(10 mins):Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2
... by the state-owned Hindustan Latex Ltd., will be launched next ... we had test marketed 30,000 pieces of female condoms across ... and women, we have decided it is time to enter ... major cities of the country,' M. Ayyappan, chairman and managing ...
... Andhra women have financed the bypass surgery of a fisherwoman ... to their efforts, B. Hemavati, 35, wife of a fisherman ... operation at the Tirupati-based Sri Venkateswara Institute of Medical Sciences ... Godavari district, was diagnosed with a heart ailment that doctors ...
... study it has been found that a herbal supplement can ... (NAC) which is a potential agent to modulate the effects ... models for the treatment of heroin addiction, and possibly alcoholism. ... herbal supplement known for its antioxidant effects. Antioxidants are agents ...
... beam computerized tomography (CBCT) is increasingly becoming a potent ... ,J. Martin Palomo and Mark Hans from the ... School of Dental Medicine and C.H. Kau and S. ... sciences at the University of Wales' College of Medicine ...
... his team from Gladstone Institute of Neurological Disease have ... for causing Alzheimer's disease //that acts by inactivating the ... to the protein fragments released from apoE. ... causing Alzheimer’s disease by not providing the glucose present ...
... important gene has been identified by the Oregon National ... (OHSU) researchers, which appears to control stem cells becoming ... conditions like Parkinson's disease and brain injury as a ... into neurons, in the early stages before birth, which ...
Cached Medicine News:Health News:Poor Andhra Women Enable Bypass Surgery Paying 50 Paise Each 2Health News:A herbal drug addiction releiver 2Health News:New Computerized Imaging Systems Help In Better Dental Treatment Planning 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: